AVITA Medical (ASX: AVH) has raised its 2026 net revenue guidance after record second-quarter revenue of US$21.7 million strengthened its expectation of reaching cash flow breakeven in the fourth quarter. Revenue increased 18% from the prior-year period and 13% sequentially, with growth across RECELL, Cohealyx, PermeaDerm, and established international markets. Quarterly net cash use fell to about US$3.2m from US$9.9m in the first quarter, while cash, cash equivalents, and marketable securities totalled US$11.1m at 30 June. AVITA retains access to an additional US$10m credit tranche if trailing 12-month net revenue reaches at least US$85m in any month before 31 March 2027, providing further financial flexibility during the expected transition to cash generation. PermeaDerm revenue increased about 40% to US$0.6m as clinicians adopted the product to temporarily stabilise and protect wounds before definitive closure, with data from the PermeaDerm I study expected in August.